Amyotrophic Lateral Sclerosis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2029

Amyotrophic Lateral Sclerosis Market Overview

Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is a severely debilitating, rare, and ultimately fatal neurodegenerative condition caused by a combination of genetic and environmental factors. However, the causative pathogenic mechanisms in ALS remain unclear. The condition is characterized by progressive degeneration of both upper (UMNs) and lower motor (LMNs) neurons that leads to death, frequently from respiratory failure, within a few years. The 8MM includes the US, France, Germany, Italy, Spain, the UK, Japan, and Canada.

The amyotrophic lateral sclerosis market research report offers an overview of amyotrophic lateral sclerosis, including its epidemiology, symptoms, diagnosis, and disease management. The report covers key topics, including strategic competitor assessment and market characterization that will help in identifying smart business strategies. In addition, the report’s data on unmet needs and clinical trial mapping will assist in understanding market gaps and making actionable predictions.

Buy the Full Report to Know More about the Amyotrophic Lateral Sclerosis Market
Download a Free Sample Report

Amyotrophic Lateral Sclerosis Market Drivers

The 12 novel ALS agents projected to launch within the next five years will be key market growth drivers. However, due to most pipeline drugs being anticipated to launch towards the end of the forecast period, the total sales contribution of the pipeline to the overall market size will remain low in 2029 with most assets not expected to realize their peak market shares at this time.

Buy the Full Report for Additional Driver Insights on the Key Amyotrophic Lateral Sclerosis Market
Download a Free Sample Report

Amyotrophic Lateral Sclerosis Market Segmentation by Countries

The key countries in the amyotrophic lateral sclerosis market are the US, France, Germany, Italy, Spain, the UK, Canada, and Japan. In 2019, the US dominated the total amyotrophic lateral sclerosis market share within the 8MM. This was due to the region’s larger disease population, availability, and anticipated launch of a wider range of assets and higher drug prices.

Amyotrophic Lateral Sclerosis Market Analysis by Countries, 2019 (%)

Buy the Full Report for Country-Wise Insights on the Amyotrophic Lateral Sclerosis Market
Download a Free Sample Report

Amyotrophic Lateral Sclerosis Market Segmentation by Drug Classes

The drug classes in the amyotrophic lateral sclerosis market include glutamate antagonists, free radical scavengers, antisense oligonucleotide, and others. In 2019, free radical scavengers contributed the highest sales to the amyotrophic lateral sclerosis market.

Amyotrophic Lateral Sclerosis Market Analysis by Drug Classes, 2019 (%)
Buy the Full Report for Drug-Class Insights on the Amyotrophic Lateral Sclerosis Market
Download a Free Sample Report

Amyotrophic Lateral Sclerosis Market Segmentation by Sponsors

The key sponsors in the amyotrophic lateral sclerosis market are AB Science, BrainStorm Therapeutics, Bruschettini, and MediciNova, among others. AB Science’s product Masitinib provides an alternative to patients who are not responsive to Rilutek and Radicava as it has a similar effect in terms of halting disease progression.

Amyotrophic Lateral Sclerosis Market Analysis by Sponsors
Buy the Full Report for Sponsor Insights on the Amyotrophic Lateral Sclerosis Market
Download a Free Sample Report

Segments Covered in this Report

Amyotrophic Lateral Sclerosis Market Country Outlook (2019-2029)

• The US
• France
• Germany
• Italy
• Spain
• UK
• Japan
• Canada

Amyotrophic Lateral Sclerosis Market Drug Classes Outlook (2019-2029)

• Glutamate Antagonists
• Free Radical Scavengers
• Antisense Oligonucleotide

Scope

The report provides:

• Overview of Amyotrophic Lateral Sclerosis, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized Amyotrophic Lateral Sclerosis therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2019 to 2029.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the ALS market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for ALS. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the 8MM ALS therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Key Highlights

Report deliverables include a PowerPoint report and an Excel-based forecast model

Forecast includes the 8 major markets (8MM)

Forecast covers the period 2019-2029.

2019 base year sales within the ALS market are approximately $318M across the 8MM detailed in this report. GlobalData estimates that the ALS market will grow at a compound annual growth rate (CAGR) of 15% to reach $1.28billion by the end of the forecast period.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 8MM ALS therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the ALS therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.